Kamuvudine-9 and Multiple Sclerosis

Listen to Post

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis or a recommendation to use any medication or experimental treatment. Kamuvudine-9 remains an investigational medicine and has not been approved as a treatment for multiple sclerosis. Anyone living with MS should discuss treatment choices, clinical trials, new symptoms or changes to prescribed medication with their neurologist, MS specialist nurse or appropriate healthcare professional. Patients should never purchase or take investigational medicines or repurpose prescription antiviral medication without medical supervision.

Could a New Experimental Drug Help Reverse Nerve Damage?

New research suggests an experimental drug derived from antiviral medicines may do more than suppress MS inflammation.

Multiple sclerosis research has produced an intriguing new development following the publication of a study involving an experimental medicine called kamuvudine-9, also known as K-9.

Researchers have reported that K-9 was able not only to prevent further neurological deterioration in a laboratory model of multiple sclerosis but also to reverse existing paralysis and vision loss in mice.

The research, published in Science Translational Medicine on 23 September 2026, has understandably generated considerable interest because one of the greatest unmet needs in MS treatment is finding therapies capable of protecting, and potentially restoring, neurological function after damage has already occurred.

However, there is an extremely important qualification.

Kamuvudine-9 has not yet been shown to reverse MS disability in humans.

As of 26 September 2026, the evidence relating specifically to multiple sclerosis comes primarily from animal research and observational human data involving related antiviral drugs. Researchers say the findings provide a strong reason to proceed towards clinical trials in people with MS, rather than evidence that K-9 is already an established MS treatment.

What Is Kamuvudine-9?

Kamuvudine-9 is an experimental drug related to a group of medicines called nucleoside reverse transcriptase inhibitors (NRTIs).

Traditional NRTIs have been widely used to treat infections including:

• HIV;
• Hepatitis B; and
• Other conditions in which viral replication needs to be suppressed.

K-9 is not simply another HIV medication. It belongs to a newer class of modified compounds known as kamuvudines, which researchers have developed to retain potentially useful anti-inflammatory properties of NRTIs while attempting to reduce some of the toxicity associated with conventional antiviral medicines.

Researchers describe K-9 as an NRTI derivative with an enhanced safety profile.

Importantly, that description should not be interpreted as meaning that K-9 has already been proven completely safe for long-term use in people with MS.

Its human safety database remains relatively small.

Why Are Scientists Interested in K-9 for Multiple Sclerosis?

MS is an autoimmune neurological condition in which the immune system mistakenly attacks structures within the central nervous system, including the protective myelin sheath surrounding nerve fibres.

Over time, inflammatory attacks and neurodegeneration can damage both myelin and the underlying nerve fibres, or axons.

Existing disease-modifying therapies can be highly effective at reducing inflammatory disease activity and relapses in some people, but repairing established neurological damage remains much more difficult.

This is why the latest K-9 findings are particularly noteworthy.

Researchers studying an experimental autoimmune encephalomyelitis model, commonly used to investigate mechanisms relevant to MS, reported that K-9:

• Prevented further neurological deficits;
• Reversed existing paralysis in the animals;
• Reversed vision loss;
• Helped preserve myelin;
• Helped preserve nerve fibres in the spinal cord; and
• Prevented an increase in neurofilament light chain (NfL), a biomarker associated with nerve damage.

These are potentially significant findings.

But what happens in an animal model does not necessarily happen in humans, which is precisely why clinical trials are now required.

What Is the Inflammasome?

One of the most interesting aspects of the research concerns structures called inflammasomes.

Inflammasomes form part of the body’s innate immune system. They act as cellular alarm mechanisms which can activate powerful inflammatory responses when cells detect infection, injury or danger.

That system is useful when responding to genuine threats.

Problems may arise, however, when inflammatory pathways become persistently or inappropriately activated.

Researchers believe abnormal inflammasome activity may contribute to neurological inflammation and tissue damage in conditions including MS.

The K-9 researchers found that the drug interfered with two pathways associated with inflammasome activation involving:

• NLRP3 and NEK7, and
• NLRP3 and NLRC4.

By disrupting these interactions, K-9 appeared to suppress inflammatory activity associated with neurological damage.

This potentially differentiates K-9 from treatments whose principal purpose is to suppress or modify the wider immune response.

Could K-9 Repair Damage Rather Than Simply Prevent It?

This is arguably the most exciting question arising from the study.

Many MS treatments concentrate primarily on preventing future inflammatory attacks.

The researchers reported that K-9 was given after neurological problems had already developed in their experimental model and that animals subsequently recovered from some existing paralysis and visual impairment.

That raises the possibility that interfering with inflammasome activity could create conditions in which neurological recovery becomes possible.

However, claims that K-9 can currently repair MS damage in humans would be premature.

The study demonstrated recovery in animals.

It did not demonstrate that a person who has lost mobility, eyesight or neurological function because of MS would regain that function after taking K-9.

Human clinical trials will have to answer that question.

What Did Researchers Find in Human Medical Records?

Alongside the laboratory work, researchers examined healthcare information involving more than three million patients.

They studied groups of people taking conventional NRTI antiviral medications for reasons including:

• HIV treatment;
• HIV pre-exposure prophylaxis; and
• Hepatitis B treatment.

Researchers observed a lower incidence of MS among people receiving NRTIs in several different patient groups.

Among people who already had MS, NRTI use was also associated with a reduction in subsequent relapses.

This is interesting because conventional NRTIs can also inhibit inflammasome activity.

However, an observational association cannot prove that the medicines themselves prevented MS or caused the reduction in relapses.

People prescribed antiviral medication may differ from other patients in numerous ways, and observational databases cannot eliminate every possible confounding factor.

The findings therefore support the biological theory behind K-9 rather than replacing a randomised clinical trial.

Is Kamuvudine-9 Currently in an MS Clinical Trial?

Not according to the currently available trial information as of 26 September 2026.

The researchers behind the latest study have said that they hope K-9 can progress into clinical studies for multiple sclerosis and other neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).

That is different from saying an MS trial has already started.

At present, K-9’s human clinical development has concentrated largely on eye conditions.

Has Kamuvudine-9 Been Tested in Humans?

Yes, but this is another distinction that needs to be made carefully.

K-9 has entered early clinical research involving humans for conditions including:

Diabetic macular oedema

A registered US Phase 1/2 clinical trial is assessing oral K-9 in people with diabetic macular oedema.

Its objectives include assessing:

• Safety;
• Treatment-related adverse events; and
• Whether K-9 improves visual acuity.

The trial registration lists an estimated enrolment of only 10 participants, illustrating how early the human development programme remains.

Thyroid eye disease

K-9 has also been investigated in an early Phase 1 study involving thyroid eye disease.

That study included pharmacokinetic testing in healthy volunteers and planned treatment in people with thyroid eye disease, but the registry subsequently listed the study as terminated, with four participants enrolled.

Earlier diabetic macular oedema research

Another K-9 study involving diabetic macular oedema was also recorded as terminated after enrolling one participant.

The existence of these studies shows that K-9 has already crossed the important boundary between purely laboratory research and human investigation.

But these studies do not establish that K-9 is safe or effective for multiple sclerosis.

Is Kamuvudine-9 Being Trialled in the UK?

At the time of writing, we could find no registered UK clinical trial testing kamuvudine-9 specifically for multiple sclerosis.

The currently registered K-9 studies identified in the public clinical-trial records are based in the United States and concern eye diseases rather than MS.

Anyone seeing headlines suggesting that K-9 represents a new MS treatment should therefore understand that the research pathway still has several steps ahead.

A future UK trial would also require the appropriate regulatory and ethical approvals before an investigational medicine could be administered to participants.

Under UK clinical-trial regulations, studies involving investigational medicinal products require clinical-trial authorisation and must comply with regulatory requirements overseen by the Medicines and Healthcare products Regulatory Agency.

Has Kamuvudine-9 “Passed Its Tests”?

Not in the sense required for an approved MS medicine.

A medicine normally passes through several stages of development.

Preclinical research

Laboratory experiments and animal studies investigate biological effects, toxicity, dosing and whether a treatment shows sufficient promise to justify human testing.

K-9 has produced promising evidence at this stage for MS.

Phase 1

Researchers primarily examine safety, tolerability, dosage and how the drug behaves inside the human body.

Phase 2

Researchers investigate safety further while beginning to determine whether the medicine produces a meaningful therapeutic effect in people with the condition being studied.

Phase 3

Much larger studies usually compare the medicine with placebo or existing treatment and establish whether its benefits outweigh its risks across a substantially larger patient population.

Regulatory assessment

Regulators then examine evidence on:

• Effectiveness;
• Safety;
• Manufacturing quality;
• Dosage;
• Interactions;
• Contraindications; and
• Overall benefit versus risk.

Only after the required regulatory approvals could K-9 become routinely prescribed as an MS treatment.

For multiple sclerosis, K-9 is therefore still at the preclinical/translational stage rather than the final approval stage.

When Could Kamuvudine-9 Become Available for MS?

There is currently no confirmed date.

Even promising medicines can take several years to move from successful animal research to regulatory approval.

Some never reach approval because later studies reveal that:

• The drug is ineffective in humans;
• The benefit is smaller than expected;
• Unexpected adverse effects occur;
• Long-term toxicity emerges;
• An effective dose cannot safely be achieved; or
• A larger clinical trial fails to reproduce earlier results.

The encouraging factor is that K-9 has already undergone some investigation in humans for other conditions, potentially providing researchers with useful early information about how the compound behaves in the human body.

But a dedicated MS development programme would still need to demonstrate safety and clinical efficacy in people living with MS.

It would therefore be inappropriate at this stage to predict a particular year in which NHS patients might receive K-9.

What Are the Side Effects of Kamuvudine-9?

This question requires particular caution.

Because K-9 remains experimental and relatively few people have received it in formal human clinical studies, there is not yet a comprehensive established side-effect profile comparable with an approved medication.

The Phase 1/2 diabetic macular oedema trial specifically includes treatment-related adverse events as one of its primary safety outcomes.

Researchers describe kamuvudines as having been designed to improve on the toxicity profile associated with conventional NRTIs, and the latest MS study describes K-9 as having favourable or appropriate safety and pharmacokinetic characteristics in the investigations carried out so far.

That does not mean the medication is known to be side-effect free.

Until substantially larger numbers of people have taken K-9, rare or delayed adverse effects may simply be impossible to identify.

Why Safety Monitoring Matters

The diabetic macular oedema clinical-trial protocol illustrates some of the areas researchers are monitoring.

Among other exclusions, the study does not allow participation by people with certain clinically significant:

• Liver abnormalities;
• Kidney abnormalities;
• Unstable medical conditions;
• Infections;
• Cancers;
• Medication interactions; or
• Hypersensitivity to components of the investigational medicine.

The trial specifically excludes people with significantly abnormal liver enzymes or severely impaired kidney filtration.

This does not establish that K-9 causes liver or kidney injury.

Clinical trials routinely impose cautious eligibility requirements precisely because researchers do not yet know the complete safety profile of an experimental medicine.

Pregnant or breastfeeding participants are also excluded from the current DME trial, while contraception requirements apply to participants who could conceive or father a child during the study period.

Again, this reflects precaution in an investigational medicine rather than proof of a particular reproductive side effect.

Could Kamuvudine-9 Interact With Other Medication?

Possibly, and this is another reason nobody should attempt to obtain or use an experimental medicine independently.

The current K-9 diabetic macular oedema study excludes people taking medicines containing NRTIs such as:

• Abacavir;
• Emtricitabine;
• Lamivudine;
• Zidovudine;
• and Several combination HIV treatments.

It also excludes certain medications associated with retinal toxicity.

Exactly which interactions will ultimately prove clinically important cannot yet be determined from such a small development programme.

K-9 Should Not Be Confused With Existing HIV Treatment

Reports describing K-9 as a modified HIV drug could easily lead people to believe that taking an existing HIV medication might have the same effect.

That should not be assumed.

The observational study involving conventional NRTIs identifies an interesting scientific association, but K-9 is a specifically modified compound.

People with MS should not start, stop, substitute or obtain antiviral medications in an attempt to reproduce the experimental results.

Medicines developed for HIV and hepatitis can have important adverse effects and interactions and should only be used for recognised clinical indications under appropriate medical supervision.

What About People With Optic Neuritis or MS-Related Vision Loss?

The visual recovery observed in the mouse study is particularly interesting because MS can damage vision through conditions including optic neuritis, in which inflammation affects the optic nerve.

The researchers reported reversal of pre-existing vision loss in their animal model.

For patients who have experienced lasting visual damage, the possibility of a future treatment capable of encouraging neurological recovery would naturally be significant.

But there is presently no evidence demonstrating that K-9 restores vision lost through MS-related optic neuritis in human patients.

That question requires a human clinical trial.

Could This Help Progressive Multiple Sclerosis?

Potentially, this is one of the questions future researchers may investigate.

Progressive MS remains particularly difficult to treat because disability can continue to accumulate independently of obvious relapses.

A therapy capable of protecting axons, preserving myelin and reducing inflammatory damage within the central nervous system could theoretically be relevant to progressive disease.

However, the September 2026 study does not establish that K-9 works in people with primary progressive MS or secondary progressive MS.

Researchers will need to determine:

• Which MS subtypes might benefit;
• Whether treatment works during active inflammation;
• Whether it helps non-active progressive disease;
• Whether lost function can genuinely return;
• What dose reaches the central nervous system effectively;
• How long treatment would be required; and
• Whether prolonged inflammasome inhibition remains safe.

Why This Research Is Still Significant

Scientific caution should not obscure why researchers are excited.

Much of modern MS treatment focuses on preventing what happens next.

The possibility of simultaneously:

• Suppressing damaging inflammation;
• Protecting nerve fibres;
• Preserving myelin;
• Reducing biomarkers associated with neurodegeneration; and
• Restoring some function that has already been lost

would represent a very different therapeutic objective.

If those effects could eventually be demonstrated in humans, the significance would extend far beyond reducing the number of future relapses.

For people already living with disability, the central question is often not simply:

“Can you stop my MS getting worse?”

It is also:

“Can anything restore some of what MS has already taken away?”

K-9 research has not yet answered that question in humans.

But for the first time, it has provided another scientifically plausible avenue through which researchers may attempt to answer it.

What Happens Next?

The logical next step is a properly designed human clinical trial specifically involving people with multiple sclerosis.

Researchers will need to examine:

• Initial safety and dosing;
• Pharmacokinetics;
• Biomarkers including neurofilament light chain;
• MRI evidence of disease activity;
• Relapse frequency;
• Disability progression;
• Walking and mobility;
• Vision;
• Upper-limb function;
• Fatigue and other symptoms;
• Neurological recovery;
• Long-term toxicity; and
• Interactions with existing disease-modifying therapies.

Particularly important will be determining whether the dramatic recovery observed in laboratory animals represents genuine neurological repair that can also occur in humans.

A Breakthrough, But Not Yet a Cure

Headlines describing a treatment that “reverses paralysis” inevitably attract attention.

The underlying research deserves attention.

But there is an enormous scientific difference between:

“A drug reversed paralysis in an experimental MS model”

and:

“A drug reverses paralysis in people with multiple sclerosis.”

At present, only the first statement is supported by evidence.

The National Institutes of Health itself describes K-9 as an experimental drug and says researchers hope to move towards clinical studies for MS.

There is no indication that K-9 has received regulatory approval as an MS medicine in the United Kingdom, and no date has been announced for routine NHS availability.

Editor’s Closing Thoughts

For people living with multiple sclerosis, particularly those who have already experienced loss of mobility, neurological impairment or damage to their eyesight, research aimed merely at preventing the next relapse is only part of the story.

The ultimate ambition must also be to understand whether damaged neurological pathways can be protected, repaired or restored.

Kamuvudine-9 is nowhere near being described as an MS cure.

Yet its ability to reverse neurological deficits in an experimental model, preserve myelin and axons and influence inflammatory mechanisms associated with neurological damage makes this a development worth watching.

The next milestone will not be another headline.

It will be whether researchers can reproduce these effects safely in human beings with multiple sclerosis.

Until those trials take place, hope must be accompanied by scientific caution.

But breakthroughs begin with discoveries, and K-9 has given MS researchers another avenue to explore.

Key Points

• Kamuvudine-9 (K-9) is experimental and is not an approved treatment for multiple sclerosis.
• A study published on 23 September 2026 reported reversal of paralysis and vision loss in an animal model of MS.
• Researchers also reported preservation of myelin and nerve fibres and effects on neurofilament light chain.
• K-9 appears to interfere with inflammasome pathways associated with inflammation.
• Analysis of more than three million people found associations between conventional NRTI use and lower MS incidence or relapse rates, but this does not prove causation.
• No human clinical trial has yet demonstrated that K-9 treats MS.
• K-9 has entered early human clinical studies for eye disorders, including diabetic macular oedema.
• There is currently no established comprehensive side-effect profile because human exposure remains limited.
• There is no confirmed UK MS clinical trial or NHS availability date for K-9 at present.
• Patients should not attempt to obtain K-9 or substitute existing antiviral medicines for prescribed MS treatment.

Sources & Further Reading

• https://www.mssociety.org.uk/research/latest-research
• https://www.science.org/doi/10.1126/scitranslmed.aei2870
• https://pmc.ncbi.nlm.nih.gov/articles/PMC8044134/
• https://www.nhs.uk/conditions/chronic-fatigue-syndrome-cfs/
• https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/neurofilament-light-chain
• https://www.sciencedirect.com/topics/neuroscience/inflammasome
• https://nwknowledgenow.nhs.uk/wp-content/uploads/2024/03/DMOPathway_PPMO_Eyes_01072025.pdf
• https://www.aaojournal.org/article/S0161-6420(23)00933-8/fulltext
• https://www.mayoclinic.org/drugs-supplements/abacavir-oral-route/description/drg-20061463
• https://www.webmd.com/drugs/emtricitabine-emtriva
• https://www.royalberkshire.nhs.uk/media/dvojnr1a/diabetic-macular-oedema_aug22.pdf
• https://www.btf-thyroid.org/thyroid-eye-disease-leaflet
• https://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30052-3/abstract
• https://www.healthline.com/health/drugs/lamivudine-oral-tablet
• https://www.mayoclinic.org/drugs-supplements/zidovudine-oral-route/description/drg-20066724
• https://www.medicaldaily.com/uva-k9-drug-multiple-sclerosis-mice-paralysis-vision-479063
• https://www.mayoclinic.org/diseases-conditions/amyotrophic-lateral-sclerosis/symptoms-causes/syc-20354022
• National Institutes of Health / National Eye Institute, Modified HIV drug reverses vision loss and paralysis in multiple sclerosis model, published 23 September 2026.
• Science Translational Medicine, Yerramothu P, Ambati K et al., The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis, 23 September 2026, DOI: 10.1126/scitranslmed.aei2870.
• ClinicalTrials.gov, NCT07458061, Randomised Trial of Kamuvudine-9 (K9) in Diabetic Macular Edema, Phase 1/2.
• UK Medicines and Healthcare products Regulatory Agency (MHRA), UK requirements governing clinical trials of investigational medicinal products.